» Articles » PMID: 6344076

Regulation of Rat Urinary and Renal Kallikrein and Prekallikrein by Corticosteroids

Overview
Specialty Science
Date 1983 May 1
PMID 6344076
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Rats were adrenalectomized and injected for 7 days with dexamethasone (DEX) or deoxycorticosterone. Kallikrein and prekallikrein were assayed in urine and in a basolateral membrane-enriched fraction. The activities of renin and phospholipase A2 were also determined in the fraction. Adrenalectomy significantly decreased active kallikrein in urine. Administration of deoxycorticosterone raised the level of active kallikrein in urine without affecting the concentration of prekallikrein. Rats treated with DEX only had high Na+ and low active kallikrein excretion. The total kallikrein level (active kallikrein together with prekallikrein), however, returned to normal because DEX elevated the prekallikrein level. DEX also increased the prekallikrein concentration in the membrane-enriched fraction. Renin activity in the membrane-enriched fraction was enhanced by adrenalectomy but suppressed by either corticosteroid. The changes in the concentration of plasma renin were qualitatively similar but quantitatively different. The activity of phospholipase A2 in the membrane-enriched fraction was enhanced only by deoxycorticosterone. Thus, both gluco- and mineralocorticoids increased kallikrein excretion in the adrenalectomized animals, but DEX was apparently effective at a lower dose than deoxycorticosterone. DEX increases the prekallikrein concentration in urine and on the basal membrane of distal tubular cells and, in addition, may prevent its conversion by releasing an inhibitor of a prekallikrein activator.

Citing Articles

Role of Kinins in Hypertension and Heart Failure.

Hamid S, Rhaleb I, Kassem K, Rhaleb N Pharmaceuticals (Basel). 2020; 13(11).

PMID: 33126450 PMC: 7692223. DOI: 10.3390/ph13110347.


The kallikrein-kinin system as a regulator of cardiovascular and renal function.

Rhaleb N, Yang X, Carretero O Compr Physiol. 2013; 1(2):971-93.

PMID: 23737209 PMC: 4685708. DOI: 10.1002/cphy.c100053.


Postnatal maturation of tissue kallikrein-producing cells (connecting tubule cells) in the rat kidney: a morphometric and immunohistochemical study.

Velarde V, Humphreys J, Figueroa C, Vio C Anat Embryol (Berl). 1995; 192(5):407-14.

PMID: 8546332 DOI: 10.1007/BF00240373.


Effect of metoprolol on 24-hour urinary excretion of adrenal steroids and kallikrein in patients with essential hypertension.

Fritschka E, Gotzen R, Kittler R, Schoneshofer M Br J Pharmacol. 1984; 81(2):245-53.

PMID: 6367871 PMC: 1986883. DOI: 10.1111/j.1476-5381.1984.tb10071.x.


Kallikrein along the rabbit microdissected nephron: a micromethod for its measurement. Effect of adrenalectomy and DOCA treatment.

Marchetti J, Imbert-Teboul M, Alhenc-Gelas F, Allegrini J, Menard J, Morel F Pflugers Arch. 1984; 401(1):27-33.

PMID: 6089089 DOI: 10.1007/BF00581529.


References
1.
Scicli A, Carretero O, Hampton A, Cortes P, Oza N . Site of kininogenase secretion in the dog nephron. Am J Physiol. 1976; 230(2):533-6. DOI: 10.1152/ajplegacy.1976.230.2.533. View

2.
Margolius H, Chao J, Kaizu T . The effects of aldosterone and spironolactone on renal kallikrein in the rat. Clin Sci Mol Med Suppl. 1976; 3:279s-282s. DOI: 10.1042/cs051279s. View

3.
Haack D, Mohring J, Mohring B, Petri M, HACKENTHAL E . Comparative study on development of corticosterone and DOCA hypertension in rats. Am J Physiol. 1977; 233(5):F403-11. DOI: 10.1152/ajprenal.1977.233.5.F403. View

4.
Yorio T, Bentley P . Phospholipase A and the mechanism of action of aldosterone. Nature. 1978; 271(5640):79-81. DOI: 10.1038/271079a0. View

5.
Okazaki T, Okita J, MACDONALD P, Johnston J . Initiation of human parturition. X. Substrate specificity of phospholipase A2 in human fetal membranes. Am J Obstet Gynecol. 1978; 130(4):432-8. View